PetIQ completed the acquisition of Capstar for $95m.

PetIQ, a pet medication and wellness company, completed the acquisition of Capstar, an oral tablet for the treatment of flea infestations on dogs, puppies, cats and kittens, for $95m. “We are excited to complete this transaction and believe Capstar’s® highly profitable product offering fits perfectly with PetIQ’s product offerings. This further advances our leadership position in helping pet parents find affordable animal health products for their pets. In a dynamic operating environment, we are very pleased that Capstar® has generated strong results year to date, increasing our confidence in its accretive growth opportunities and long-term value creation," Cord Christensen, PetIQ Chairman and CEO.